Hong Kong, June 11, 2009 (JCN Newswire) - The Board of Mingyuan Medicare Development Company Limited ("Mingyuan Medicare" or the "Company", Stock code: 0233) is pleased to announce today that the Company had entered into a milestone co-operation agreement (the "Co-operation Agreement") with Chinese National Human Genome Centre in Shanghai ("CHGC") and Shanghai Biochip Company Limited ("SBC") on the joint establishment of an uniquely dynamic technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases on demand basis. The platform is important for the industrialization of high-tech national medical products.
